In Picking Up Affy's CLIA Lab is Navigenics Inviting More Regulatory Woes? | GenomeWeb

With its recent acquisition of Affymetrix’s Clinical Laboratory Improvement Amendments-compliant laboratory, Navigenics has delved into the complicated and confusing world of laboratory regulation, but the personal genomics firm is focusing on the advantages of having an internal lab than the potential regulatory challenges.

“There are no regulatory implications on the federal level and on the state level we will have the licenses that Affy has,” Vance Vanier, Navigenics chief medical officer, told Pharmacogenomics Reporter this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.